Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00001292
Other study ID # 920106
Secondary ID 92-C-0106
Status Completed
Phase N/A
First received November 3, 1999
Last updated March 4, 2008
Start date February 1992
Est. completion date April 2001

Study information

Verified date April 2000
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The purpose of this study is to identify the genes responsible for certain scaling disorders and other inherited skin diseases and to learn about the medical problems they cause. In some cases, these may include problems affecting organs other than the skin, such as the eyes, teeth and bones.

Patients with inherited skin disorders, including Darier's disease (keratosis follicularis), lamellar ichthyosis, epidermolysis bullosa, cystic acne, and others, and their relatives may be eligible for this study. Patients will have a medical history, physical examination with particular emphasis on the skin, and routine blood tests. Additional procedures for patients and unaffected relatives may include:

1. Blood sample collection

2. Dental exam with X-ray of the jaw

3. Eye examination

4. X-rays of the skull, ribs, chest, hands, feet, spine, arms, or legs

5. Bone density scan

6. Photographs of the skin

7. Skin biopsies (removal of a small tissue sample under local anesthetic)

8. Buccal sample (gentle brushing inside the cheek to collect a cell sample) for gene studies

Patients who request the results of their gene testing will be provided this information.


Description:

We propose to investigate the genetics of the scaling disorders and other genodermatoses which are believed to behave in a Mendelian manner. Families for study will be ascertained through articles in the Ichthyosis Focus, (the newsletter of the Foundation for Ichthyosis and Related Skin Types), physician referrals, and patient self-referrals. Efforts will be made to further characterize the clinical findings in both affected persons and unaffected gene carriers. Using candidate genes, especially those known to be involved in structural abnormalities of skin, we will attempt to map and isolate major genes contributing to expression of the disease phenotype. Failing this direct approach, a random search of the genome (so-called, "reverse genetics") will be utilized. In addition, normal and diseased skin will be used in cell culture and animal experiments (under a separate protocol) to test new therapeutic modalities.


Recruitment information / eligibility

Status Completed
Enrollment 0
Est. completion date April 2001
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A and older
Eligibility No steroid sulfatase deficiency.

Study Design

N/A


Locations

Country Name City State
United States National Cancer Institute (NCI) Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (2)

DiGiovanna JJ, Bale SJ. Epidermolytic hyperkeratosis: applied molecular genetics. J Invest Dermatol. 1994 Mar;102(3):390-4. Review. — View Citation

Russell LJ, DiGiovanna JJ, Rogers GR, Steinert PM, Hashem N, Compton JG, Bale SJ. Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat Genet. 1995 Mar;9(3):279-83. — View Citation

See also
  Status Clinical Trial Phase
Not yet recruiting NCT01222000 - Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Phase 3
Terminated NCT03738800 - A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis Phase 2
Completed NCT03041038 - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Phase 2